Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells

Toxicology and Applied Pharmacology

Volumn 255, Issue 3, 2011, Pages 327-338

  Ko, Jen Chung ^a,b,c   Tsai, Min Shao ^d   Weng, Shao Hsing ^d   Kuo, Ya Hsun ^d   Chiu, Yu Fan ^d   Lin, Yun Wei ^d  

^a Hsinchu Hospital   (Taiwan)

^b YUANPEI UNIVERSITY   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Curcumin; Cytotoxicity; Mitomycin C; Non small cell lung cancer; Rad51

Indexed keywords

CURCUMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOMYCIN C; RAD51 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CURCUMIN; CYTOTOXINS; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOMYCIN; RAD51 RECOMBINASE; RNA, SMALL INTERFERING;

CURCUMA LONGA;

EID: 80052350982     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.07.012     Document Type: Article

References (50)

1. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23:363-398.
2. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., Price J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 2005, 11:7490-7498.
3. Ammon H.P., Wahl M.A. Pharmacology of Curcuma longa. Planta Med. 1991, 57:1-7.
4. Arnaudeau C., Helleday T., Jenssen D. The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. J. Mol. Biol. 1999, 289:1231-1238.
5. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 2008, 26:3785-3790.
6. Babiak A., Hetzel J., Godde F., Konig H.H., Pietsch M., Hetzel M. Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC-a phase II trial. Br. J. Cancer 2007, 96:1052-1056.
7. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., Loda M., Weber G., Mark E.J., Lander E.S., Wong W., Johnson B.E., Golub T.R., Sugarbaker D.J., Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 2001, 98:13790-13795.
8. Booton R., Lorigan P., Anderson H., Baka S., Ashcroft L., Nicolson M., O'Brien M., Dunlop D., O'Byrne K., Laurence V., Snee M., Dark G., Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann. Oncol. 2006, 17:1111-1119.
9. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 2008, 8:180-192.
10. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
11. Chan M.M., Fong D., Soprano K.J., Holmes W.F., Heverling H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J. Cell. Physiol. 2003, 194:63-70.
12. Chan N., Koritzinsky M., Zhao H., Bindra R., Glazer P.M., Powell S., Belmaaza A., Wouters B., Bristow R.G. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 2008, 68:605-614.
13. Chen Y.R., Tan T.H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998, 17:173-178.
14. Chen L., Tian G., Shao C., Cobos E., Gao W. Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells. Mol. Biol. Rep. 2010, 37:3105-3110.
15. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer. Res. 2001, 21:2895-2900.
16. Collett G.P., Campbell F.C. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004, 25:2183-2189.
17. Daboussi F., Dumay A., Delacote F., Lopez B.S. DNA double-strand break repair signalling: the case of RAD51 post-translational regulation. Cell. Signal. 2002, 14:969-975.
18. Dronkert M.L., Kanaar R. Repair of DNA interstrand cross-links. Mutat. Res. 2001, 486:217-247.
19. Du B., Jiang L., Xia Q., Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006, 52:23-28.
20. Godthelp B.C., Wiegant W.W., van Duijn-Goedhart A., Scharer O.D., van Buul P.P., Kanaar R., Zdzienicka M.Z. Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res. 2002, 30:2172-2182.
21. Han S.S., Keum Y.S., Seo H.J., Surh Y.J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol. 2002, 35:337-342.
22. Helleday T., Lo J., van Gent D.C., Engelward B.P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007, 6:923-935.
23. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
24. Klein H.L. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 2008, 7:686-693.
25. Ko J.C., Ciou S.C., Cheng C.M., Wang L.H., Hong J.H., Jheng M.Y., Ling S.T., Lin Y.W. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008, 29:1448-1458.
26. Ko J.C., Ciou S.C., Jhan J.Y., Cheng C.M., Su Y.J., Chuang S.M., Lin S.T., Chang C.C., Lin Y.W. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Mol. Cancer Res. 2009, 7:1378-1389.
27. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J. Clin. 1999, 49(8-31):31.
28. Levi M.S., Borne R.F., Williamson J.S. A review of cancer chemopreventive agents. Curr. Med. Chem. 2001, 8:1349-1362.
29. Luoto K.R., Meng A.X., Wasylishen A.R., Zhao H., Coackley C.L., Penn L.Z., Bristow R.G. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 2010, 70:8748-8759.
30. McHugh P.J., Spanswick V.J., Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001, 2:483-490.
31. Mladenov E., Anachkova B., Tsaneva I. Sub-nuclear localization of Rad51 in response to DNA damage. Genes Cells 2006, 11:513-524.
32. Mladenov E., Tsaneva I., Anachkova B. Activation of the S phase DNA damage checkpoint by mitomycin C. J. Cell. Physiol. 2007, 211:468-476.
33. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., Olak J., Stover D., Strawn J.R., Turrisi A.T., Somerfield M.R. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 2004, 22:330-353.
34. Qiao G.B., Wu Y.L., Yang X.N., Zhong W.Z., Xie D., Guan X.Y., Fischer D., Kolberg H.C., Kruger S., Stuerzbecher H.W. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 2005, 93:137-143.
35. Radhakrishna Pillai G., Srivastava A.S., Hassanein T.I., Chauhan D.P., Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 2004, 208:163-170.
36. Rao C.V., Rivenson A., Simi B., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995, 55:259-266.
37. Richardson C. RAD51, genomic stability, and tumorigenesis. Cancer Lett. 2005, 218:127-139.
38. Richardson C., Stark J.M., Ommundsen M., Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004, 23:546-553.
39. Ruby A.J., Kuttan G., Babu K.D., Rajasekharan K.N., Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 1995, 94:79-83.
40. San Filippo J., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008, 77:229-257.
41. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J. Med. 2002, 346:92-98.
42. Sen S., Sharma H., Singh N. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem. Biophys. Res. Commun. 2005, 331:1245-1252.
43. Singh S., Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 1995, 270:24995-25000.
44. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., Shoji F., Maehara Y. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 2007, 121:895-900.
45. Tsai M.S., Kuo Y.H., Chiu Y.F., Su Y.C., Lin Y.W. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J. Pharmacol. Exp. Ther. 2010, 335:830-840.
46. Tsai M.S., Weng S.H., Kuo Y.H., Chiu Y.F., Lin Y.W. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol. Pharmacol. 2011, 80:136-146.
47. Vispe S., Cazaux C., Lesca C., Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 1998, 26:2859-2864.
48. Warren A.J., Hamilton J.W. Synthesis and structural characterization of the N2G-mitomycin C-N2G interstrand cross-link in a model synthetic 23 base pair oligonucleotide DNA duplex. Chem. Res. Toxicol. 1996, 9:1063-1071.
49. Weir N.M., Selvendiran K., Kutala V.K., Tong L., Vishwanath S., Rajaram M., Tridandapani S., Anant S., Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol. Ther. 2007, 6:178-184.
50. Zhou Q.M., Zhang H., Lu Y.Y., Wang X.F., Su S.B. Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts. Cancer Sci. 2009, 100:2040-2045.